Floatz logo

Resiquimod

Anaplastic Astrocytoma

Jonsson Comprehensive Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Anaplastic Astrocytoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2/3BB
Carboplatin
Oliver Jonas
Phase 2BB
Trametinib
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Resiquimod is also rated in:

melanomaActive
B
Indicative · Phase 2
62 / 100
View asset →
neoplasmActive
B
Indicative · Phase 2
61 / 100
View asset →
anaplastic oligoastrocytomaDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →